Scarica l'app Stockscreener
8.76
1.24%
-0.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché OCUL Giù?
Forum
Previsione
Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie
Is Ocular Therapeutix (OCUL) Pricing Reflect Its Volatile Returns And Rich Sales Multiple? - simplywall.st
Sanofi Rumored Bid And Regulatory Shifts Reframe Ocular Therapeutix Valuation - Sahm
Ocular Therapeutix Opens with 8.61% Gain Amid Ongoing Financial Challenges - Markets Mojo
Ocular Therapeutix Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
Pharma Sector Q1 2026 Earnings Review: Mixed Results & Future OutlookNews and Statistics - IndexBox
Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL) - Yahoo Finance
Ocular Therapeutix at The Citizens Life Sciences Conference: AXPAXLI’s Promising Results - Investing.com Canada
OCUL: AXPAXLI's phase III success sets a new standard in wet AMD, with regulatory approval in progress - TradingView
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Rhenman & Partners Asset Management AB Buys Shares of 202,000 Ocular Therapeutix, Inc. $OCUL - MarketBeat
Can Ocular Therapeutix Inc. stock surprise with earnings upsideJuly 2025 Intraday Action & Technical Buy Zone Confirmation - Naître et grandir
Ocular Therapeutix Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Why Ocular Therapeutix (OCUL) Is Up 16.2% After Detailing Retinal Pipeline Progress And Upcoming Milestones - Sahm
Ocular Therapeutix, Inc. $OCUL Shares Bought by Vanguard Group Inc. - MarketBeat
New Ocular Therapeutix Price Target as Stock Prepares to Blow Through the Old One - TheStreet Pro
Ocular Therapeutix, Inc. (OCUL) Competitors - Meyka
Ocular Therapeutix (OCUL) Gets a Buy from Piper Sandler - The Globe and Mail
Ocular Therapeutix, Inc. (OCUL) Presents at 49th Annual Meeting of the Macula SocietySlideshow - Seeking Alpha
GE Aerospace To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Ocular Therapeutix, Inc. (OCUL) Stock Analysis: 136% Potential Upside Captivates Investor Interest - DirectorsTalk Interviews
Ocular Therapeutix Stock Jumps 22.8% After Conference Update Ahead of Earnings - TIKR.com
Ocular Therapeutix (OCUL): Analyst Raises Price Target Amid Stea - GuruFocus
Short Interest in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Grows By 27.8% - MarketBeat
William Blair Maintains Outperform on Ocular Therapeutix, Inc. (OCUL) March 2026 - Meyka
Ocular Therapeutix Breaks Above 200-Day Moving AverageBullish for OCUL - Nasdaq
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 17.4%Should You Buy? - MarketBeat
Ocular Therapeutix, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Ocular Therapeutix at TD Cowen Conference: Strategic Insights on AXPAXLI By Investing.com - Investing.com Canada
OCUL: Superiority achieved in retina study, paving way for broad label and premium market position - TradingView
Ocular Therapeutix Director Pravin Dugel Sells Shares - TradingView
Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Swings And AXPAXLI Expectations - Yahoo Finance
Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory - Yahoo Finance
Ocular Therapeutix Shares Fall After Inflation Report | 2026 Market UpdateNews and Statistics - IndexBox
Ocular Therapeutix (NASDAQ:OCUL) Cut to Sell at Wall Street Zen - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Is Ocular Therapeutix (OCUL) Pricing Reflecting Its Recent Volatility And DCF Implied Upside - simplywall.st
Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why - Yahoo Finance
Ocular Therapeutix Highlights Phase 3 AXPAXLI Trial Progress - TipRanks
Ocular Therapeutix to Release SOL-1 Phase 3 AXPAXLI Trial Slides at Macula Society Meeting - TradingView
Ocular Therapeutix chief development officer Kaiser sells $23k in stock - Investing.com India
Sanjay Nayak Sells 1,759 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock - MarketBeat
Peter Kaiser Sells 2,810 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock - MarketBeat
Jeffrey Heier Sells 3,057 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $166,063.68 in Stock - MarketBeat
Ocular Therapeutix, Inc. (OCUL) Investor Outlook: A Biotech With A 205% Potential Upside - DirectorsTalk Interviews
Ocular Therapeutix (NASDAQ:OCUL) Insider Nadia Waheed Sells 3,510 Shares - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Director Richard Md Lindstrom Acquires 60,229 Shares - MarketBeat
Waheed Nadia, Ocular Therapeutix CMO, sells $27k in stock By Investing.com - Investing.com Canada
Waheed Nadia, Ocular Therapeutix CMO, sells $27k in stock - Investing.com South Africa
Ocular Therapeutix Forms Death Cross, Signaling Potential Bearish Trend Ahead - Markets Mojo
Ocular Therapeutix to Participate in March Investor Conferences - Bitget
Ocular Therapeutix™ to Participate in March Investor Conferences - The Manila Times
Ocular Therapeutix Shares Jump After AXPAXLI Hits SOL-1 Phase 3 Endpoint in Wet AMD - MarketBeat
Ocular To Present Detailed Phase 3 SOL-1 Data For AXPAXLI At The 49th Macula Society Annual Meeting - Nasdaq
A Look At Ocular Therapeutix (OCUL) Valuation After Axpaxli Phase 3 SOL-1 Data And Share Price Drop - simplywall.st
Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations - The Manila Times
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):